Identification of Significant Proteins in Hypertension Using The Clustering Molecular Complex Detection (MCODE) Method

Lusi Agus Setiani; Wisnu Ananta Kusuma; Silvia Alviani Zulkarnaen

doi:10.33751/komputasi.v20i2.7905

Identification of Significant Proteins in Hypertension Using The Clustering Molecular Complex Detection (MCODE) Method

Lusi Agus Setiani, Wisnu Ananta Kusuma, Silvia Alviani Zulkarnaen

Abstract

Hypertension is a condition where the systolic blood pressure value is more than 140 mmHg and the diastolic blood pressure value is more than 90 mmHg. A significant protein is a protein that has the greatest effect or is the center of protein regulation in all biochemical processes. The purpose of this study was to determine the significant protein that has the greatest ef- fect on hypertension by using the clustering Molecular Complex Detection (MCODE) method which will identify areas in the network with the highest density value locally and to determine the mechanism of action of the significant proteins obtained in the setting blood pressure using Gene Ontology and Kyoto Encyclopedia and Genome Analysis (KEGG) by looking at protein signaling pathways for hypertension. The results showed that the STAT3, MAPK3, AKT1, and EDN1 proteins were significant proteins involved in the mechanism of the response to leptin, the ERK1 and ERK2 cascades, the process of nitric oxide biosynthesis, and the cellular response to ROS.

Keywords

Hypertension; MCODE; PPI; Node; Edges

References

B. Williams et al., 2018 ESC/ESHGuidelines for themanagement ofarterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH), vol. 39, no. 33. 2018.

J. Ran et al., “Construction and analysis of the protein-protein interaction network related to essential hypertension,” BMC Syst. Biol., vol. 7, hal. 32, 2013.

WHO, “More than 700 million people with untreated hypertension,” 2021.

J. Li, X. Zhu, dan J. Y. Chen, “Building Disease-Specific Drug-Protein Connectivity Maps from Molecular Interaction Networks and PubMed Abstracts,” PLoS Comput. Biol., vol. 5, no. 7, 2009.

J. Chang, Y. Zhou, M. Tahir, U. Qamar, L. Chen, dan Y. Ding, “Prediction of Protein – Protein Interactions by Evidence Combining Methods,” Int. J. Mol. Sci., vol. 17, hal. 1946, 2016.

C. Qin, Y. Sun, dan Y. Dong, “A New Method for Identifying Essential Proteins Based on Network Topology Properties and Protein Complexes,” Plose One, hal. 1–30, 2016.

S. Damayanti, K. Khonsa, dan T. Amelia, “Antiviral Activity and Toxicity Prediction of Compounds Contained in Figs (Ficus carica L.) by In Silico Method,” Indones. J. Pharm. Sci. Technol., vol. 8, no. 1, hal. 21, 2021.

M. R. Diansyah, W. A. Kusuma, dan A. Annisa, “Identification of significant protein in protein-protein interaction of Alzheimer disease using top-k representative skyline query,” J. Teknol. dan Sist. Komput., vol. 9, no. 3, hal. 126–132, 2021.

M. R. Diansyah dan W. A. Kusuma, “Analysis of Protein-Protein Interaction Using Skyline Query on Parkinson Disease,” ICACSIS, hal. 175–180, 2019.

M. S. Usman, “Identifikasi Protein-Protein Signifikan Yang Berasosiasi Dengan Diabetes Meli- tus (DM) Tipe 2 Menggunakan Analisis Topologi Jejaring Protein-Protein Interaction,” In- stitut Pertanian Bogor, 2016.

R. E. Roberts, “The extracellular signal-regulated kinase (ERK) pathway: a potential thera- peutic target in hypertension,” J. Exp. Pharmacol., hal. 77, 2012.

J. M. Ha et al., “Regulation of arterial blood pressure by Akt1-dependent vascular relaxation,” J. Mol. Med., vol. 89, no. 12, hal. 1253–1260, 2011.

REFERENCES 91

K. Nikola, Springer Handbook of Bio- / Neuroinformatics. London New York: Springer. New

Zealand., 2014.

K. James dan P. D. Olson, “The tapeworm interactome: Inferring confidence scored protein- protein interactions from the proteome of Hymenolepis microstoma,” BMC Genomics, vol. 21, no. 1, hal. 346, 2020.

S. Harun dan N. Zullkifle, “Construction and Analysis of Protein Protein Interaction Network to Identify the Molecular Mechanism in Laryngeal Cancer,” Sains Malaysiana, vol. 47, no. 12, hal. 2933–2940, 2018.

Y. Lin, F. Wang, L. Cheng, Z. Fang, dan G. Shen, “Identification of Key Biomarkers and Immune In fi ltration in Sciatic Nerve of Diabetic Neuropathy BKS-db / db Mice by Bioin- formatics Analysis,” Front. Pharmacol, vol. 12, hal. 1–13, 2021

N. Bhattacharyya et al., “CDK1 and HSP90AA1 Appear as the Novel Regulatory Genes in Non-Small Cell Lung Cancer: A Bioinformatics Approach,” J. Pers. Med., vol. 12, no. 3, hal. 0–1, 2022.

G. Scardoni, M. Petterlini, dan C. Laudanna, “Analyzing biological network parameters with CentiScaPe,” Bioinformatics, vol. 25, no. 21, hal. 2857–2859, 2009.

R. Paulin, J. Meloche, dan S. Bonnet, “STAT3 signaling in pulmonary arterial hypertension,” ResearchGate, vol. 1, no. 4, 2012.

M. Y. Lee et al., “Regulation of Vascular Tone and Ischemia-Induced Arteriogenesis,” AHA J., hal. 870–879, 2018.

K. Kostov, “The Causal Relationship between Endothelin-1 and Hypertension: Focusing on Endothelial Dysfunction , Arterial Stiffness , Vascular Remodeling , and Blood Pressure Regulation,” Life, vol. 11, hal. 986, 2021.

P. Ferroni, D. Della-morte, R. Palmirotta, T. Rundek, F. Guadagni, dan M. Roselli, “Angio- genesis and Hypertension: The Dual Role of Anti-Hypertensive and Anti-Angiogenic Thera- pies,” Curr. Vasc. Pharmacol., vol. 10, hal. 479–493, 2012.

M. Rouabhi, D. Guo, D. A. Morgan, Z. Zhu, dan M. López, “BBSome ablation in SF1 neurons causes obesity without comorbidities,” Mol. Metab., vol. 48, no. March, hal. 101211, 2021.

T. W. Kurtz, S. E. Dicarlo, dan R. C. M. Jr, “Logical Issues With the Pressure Natriuresis Theory of Chronic Hypertension,” Am. J. Hypertens., vol. 29, no. December, hal. 1325–1331, 2016.

I. R. Barrows, A. Ramezani, dan D. S. Raj, “Imflammation, Immunity and Oxidative Stress in Hypertension - Partners in Crime,” Adv. Chronic Kidney Dis., vol. 26, no. 2, hal. 122–130, 2019.

Y. Hirooka, T. Kishi, K. Sakai, A. Takeshita, dan K. Sunagawa, “Imbalance of central ni- tric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension,” AJP-Regul Integr Comp Physiol, vol. 300, hal. 818–826, 2011.

E. Schulz, T. Gori, dan T. Mu, “Oxidative stress and endothelial dysfunction in hypertension,” Hypertens. Res., vol. 34, hal. 665–673, 2011.

D. Ma et al., “Leptin is associated with blood pressure and hypertension in women from the National Heart, Lung, and Blood Institute family heart study,” Hypertension, vol. 53, no. 3, hal. 473–479, 2009.

S. Becerril et al., “Functional Relationship between Leptin and Nitric Oxide in Metabolism,” Nutrient, vol. 11, hal. 2129, 2019.

M. B. Ernst et al., “Enhanced Stat3 activation in POMC neurons provokes negative feed- back inhibition of leptin and insulin signaling in obesity,” J. Neurosci., vol. 29, no. 37, hal. 11582–11593, 2009.

R. M. Touyz dan A. M. Briones, “Reactive oxygen species and vascular biology: implications in human hypertension,” Hypertens. Res., no. October 2010, hal. 5–14, 2011.

G. Togliatto, G. Lombardo, dan M. F. Brizzi, “The Future Challenge of Reactive Oxygen Species ( ROS ) in Hypertension: From Bench to Bed Side,” Int. J. Mol. Sci., vol. 18, hal. 1988, 2017.

M. Y. Lee, A. K. Luciano, E. Ackah, J. Rodriguez-vita, T. A. Bancroft, dan A. Eichmann, “Endothelial Akt1 mediates angiogenesis by phosphorylating multiple angiogenic substrates,” PNAS, vol. 111, no. 35, 2014.

A. Bradley, D. Punihaole, dan T. Barry, “Characterization of the Role of Nitric Oxide and Its Clinical Applications,” Cardiology, vol. 122, hal. 55–68, 2012.

M. Hermann, A. Flammer, dan T. F. Lüscher, “Nitric Oxide in Hypertension,” J. Clin. Hy- pertens., vol. 8, no. 12, hal. 17–29, 2006.

D. Alonso dan M. W. Radomsk, “The Nitric Oxide-Endothelin-1 Connection The Nitric Oxide-Endothelin-1 Connection,” Kluwer Acad. Publ., vol. 8, hal. 107–115, 2003.

M. Sarwar, X. Du, T. B. Dschietzig, dan R. J. Summers, “The actions of relaxin on the human cardiovascular system,” Br. J. Pharmacol., vol. 174, hal. 933–949, 2017.

S. L. Teichman et al., “Relaxin , a pleiotropic vasodilator for the treatment of heart failure,” Hear. Fail Rev, vol. 14, hal. 321–329, 2009.

A. Gonzalez-guerra et al., “Sustained Elevated Blood Pressure Accelerates Atherosclerosis Development in a Preclinical Model of Disease,” Int. J. Mol. Sci., vol. 22, hal. 8448, 2021.

Q. Chen et al., “Theranostics Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis,” Ivyspring, vol. 9, no. 22, 2019.

A. J. Muslin, “MAPK Signaling in Cardiovascular Health and Disease: Molecular Mechanisms and Therapeutic Targets,” Natl. Institutes Heal., vol. 115, no. 7, hal. 203–218, 2009.

C. Fernández-Hernando et al., “Loss of Akt1 leads to severe atherosclerosis and occlusive coronary artery disease,” Natl. Institutes Heal., vol. 6, no. 6, hal. 446–457, 2013.

Full Text: PDF

DOI: 10.33751/komputasi.v20i2.7905